Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of QHRD107 + venetoclax + azacitidine in newly diagnosed acute myeloid leukemia unfit for intensive induction chemotherapy
CTR20263089Phase 2Active
- Sponsor
- Qianhong Biopharmaceutical
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QHRD107, venetoclax and azacitidine in acute myeloid leukemia (AML), sponsored by Qianhong Biopharmaceutical. Primary endpoint: Composite complete remission rate. Started Aug 2026; status: active.
02
Drugs
QHRD107venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20263089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263089.